Orion Corporation (Finnish company)

This article is about the pharmaceutical company. For other companies named Orion, see Orion (disambiguation).

Orion Corporation

Native name	Orion Oyj
Company type	Julkinen osakeyhtiö
Traded as	Nasdaq Helsinki:  ORNAV, ORNBV
Industry	Pharmaceutical industry
Founded	21 September 1917;107 years ago (1917-09-21)
Headquarters	Espoo, Finland
Key people	Liisa Hurme (President and CEO), Mikael Silvennoinen (Chairman)
Products	Pharmaceuticals and active pharmaceutical ingredients
Revenue	€1.041 billion (2021)
Operating income	€243.3 million (2021)
Net income	€193.8 million (2021)
Total assets	€1.114 billion (2021)
Total equity	€747.9 million (2021)
Number of employees	3,364 (2021)
Website	www.orionpharma.com
Footnotes /references [1]

Orion Corporation (Finnish : Orion Oyj), ^{[2] [3]} founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland. ^[4]

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

History

Orion was founded on September 21, 1917 by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding Orion, they worked in a pharmaceutical-chemical factory called Medica. The first premises of the new company were found in a courtyard building in Helsinki's Kruununhaka, Mariankatu 24, i.e. Asunto Oy Mars star. Among the first products of the apothecary were Ballistol gun oil and dulcine. ^[5] Pediatrician Arvo Ylppö played a significant role starting in the 1920s. ^[6]

Orion's diagnostics business was previously concentrated in the Orion Diagnostica profit unit, which was sold to a private equity investor in April 2018. ^[7] The diagnostics business included the development, manufacture and marketing of diagnostic tests and hygiene tests. Orion Diagnostica changed its name in November 2019 and is now Aidian. ^[8]

Notable products

The following are Orion's top-selling product lines as of March 2021. ^[9]

Trade name	Generic name	Indication
Stalevo,Comtess/ Comtan	Entacapone	Parkinson's disease
Easyhaler	multi-dose dry-powder inhaler for asthma.	asthma, COPD
Simdax	Levosimendan	acute heart failure
dexdor	dexmedetomidine	intensive care sedative
Dexdomitor	dexmedetomidine	animal sedative
Domitor	medetomidine	animal sedative
Domosedan	detomidine	animal sedative
Antisedan	atipamezole	reversing agent
Nubeqa	Darolutamide	non-metastatic castration-resistant prostate cancer
Solomet	Methylprednisolone	inflammation
Divina series	Estradiol valerate and Medroxyprogesterone acetate	hormone replacement against menopausal symptoms
Fareston	Toremifene	Selective estrogen receptor modulator
Burana	ibuprofen	inflammatory pain
Marevan	warfarin	anticoagulant

References

1. "Orion Group - Financial Statement Release 2021" (PDF). Archived from the original (PDF) on 16 February 2022.
2. "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
3. "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
4. "About Orion".
5. "Orionin virstanpylväitä 1910-luvulla". www.orion.fi. Archived from the original on 25 July 2022. Retrieved 25 July 2022.
6. "Orionin vahva mies | Arvo Ylppö". www.ylppo.fi. Retrieved 25 July 2022.
7. Moran, Mark (18 May 2018). "AJP Board Member Responds to NYT Story On Antidepressant Withdrawal" . Psychiatric News. 53 (10). doi:10.1176/appi.pn.2018.5b14. ISSN   0033-2704.
8. "Orion Diagnostica on nyt Aidian". Aidian (in Finnish). Retrieved 25 July 2022.
9. "Orion Result Presentation 1−3/2021" (PDF). Archived from the original (PDF) on 14 June 2021.

External links

• Official website